Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Compare tax treatment for index funds in Roth and Traditional IRAs, focusing on after-tax benefits and strategic planning.
28,316 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
OpenAI reports Codex downloads exceed 1 million with over 1 million weekly active users, signaling a shift toward Cod...
SanDisk, Micron and Western Digital nosedived as investors cash in after a rapid AI memory rally, signaling a pause i...
AMD posts a 55% month gain as AI data center demand accelerates, eclipsing Intel’s advance. The move sparks a debate ...
DTE Energy is nearing its 52-week high after a robust first half of 2026, supported by utility earnings and a rising ...
Nvidia remains the AI chip leader, but Broadcom and Marvell are gaining ground as hyperscalers push for lower costs t...
Air France will suspend flights to Havana for several weeks as Cuba faces a worsening fuel shortage and a weakened ec...
Chevron reports stronger-than-expected Q1 2026 results and advancing Hess synergy-driven production, but investors de...
Tired of trying to time the market? This guide shows a simple, proven path: buy solid dividend stocks and hold them f...
A high-ranking Google DeepMind AI executive leaves for OpenAI, triggering investor chatter about Alphabet stock and t...
Jim Cramer's ongoing Nvidia purchases rest on one core belief: the CUDA software moat that underpins Nvidia's AI lead...
Anthropic’s safety-first AI stance is colliding with government pressure, placing its investors in a pivotal role as ...